期刊
PHARMACOGENOMICS
卷 18, 期 12, 页码 1125-1132出版社
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2017-0080
关键词
CYP2D6(star)2; endoxifen; enhancer; rs5758550; tamoxifen
Aim: CYP2D6(star)2 is considered fully active, but it has been suggested that it only happens in the presence of rs5758550. This study aims to elucidate the impact of this enhancer. Materials & methods: DNA and blood samples from women enrolled in the CYPTAM study (NTR1509) were analyzed. Fourteen CYP2D6(star)2 carriers without the enhancer were reclassified. The relationship of CYP2D6 phenotypes and drug levels was studied. Results: After correction for the absence of the enhancer, the correlation between CYP2D6 phenotypes and endoxifen did not improve (R-2: 0.290 vs 0.279). No difference was observed in mean concentrations between CYP2D6(star)2 individuals with and without the enhancer. Conclusion: The rs5758550 enhancer does not lead to improved prediction of endoxifen levels in breast cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据